Morphic Medical Appoints Terri Cooper to Strengthen its Board of Directors

Morphic Medical's Leadership Boost with Terri Cooper's Appointment

Morphic Medical, the pioneering company behind the world’s first medical device specifically created to address the root cause of type 2 diabetes, has announced an important addition to its Board of Directors. The appointment of Dr. Terri Cooper, a seasoned professional with extensive experience in the healthcare and life sciences sector, marks a significant step in the company’s mission to advance metabolic health.

Terri Cooper's Remarkable Background

With an impressive career spanning over 35 years, Dr. Terri Cooper stands out as a prominent figure in the healthcare industry. Her diverse experience encompasses both public and private sectors, where she has held key leadership roles that shaped healthcare practices globally. Before joining Morphic Medical, Dr. Cooper was the Director of the Consulting Practice at Deloitte in the United States. Here, she successfully built the life sciences R&D business while steering global organizational and financial restructurings that led to significant performance enhancements.

Dr. Cooper is recognized for her contribution to regulatory strategy, business technology, brand development, and compliance imperatives within the complex healthcare landscape. She has embarked on numerous initiatives aimed at fostering innovation through mergers, acquisitions, and creating growth opportunities.

A Vision for Metabolic Health

In her new role, Dr. Cooper expressed her excitement about joining Morphic Medical at this pivotal moment for the evolution of metabolic health solutions. "I am honored to join the Board of Directors of Morphic Medical at such a crucial time for the evolution of metabolic health," she stated. "The company's commitment to developing less invasive, patient-centered solutions represents the type of innovation our healthcare system desperately needs. I look forward to supporting the team in their efforts to expand access and improve outcomes for patients suffering from obesity and type 2 diabetes."

Strategic Direction for the Future

Mike Gutteridge, Morphic Medical’s President and CEO, shared his enthusiasm for Dr. Cooper’s appointment, emphasizing her extensive experience in life sciences and healthcare leadership. "We are delighted to welcome Dr. Terri Cooper to Morphic Medical's Board of Directors. She brings over three decades of global leadership with profound expertise in strategy, regulatory management, organizational transformation, and value creation. Her insights will be crucial as we progress through our clinical trial STEP-1 in the United States and continue to build the clinical and commercial foundation of RESET® – our incisionless endoscopic therapy designed to achieve rapid weight loss and significant metabolic improvement for patients with obesity and type 2 diabetes."

What is RESET®?

Founded in 2003 and based in Boston, Massachusetts, Morphic Medical is at the forefront of innovative healthcare solutions. The company develops RESET, an endoscopically delivered therapy for morbid obesity and/or obesity in the presence of concurrent cardiometabolic risk factors, such as type 2 diabetes and dyslipidemia. It is important to note that RESET is not yet approved for sale in the United States and is restricted by federal law to research purposes only.

In conclusion, the strategic appointment of Dr. Cooper is a promising advancement for Morphic Medical as it navigates the complexities of the healthcare sector while remaining committed to pushing the boundaries of what is possible in treating metabolic diseases. By leveraging her knowledge and experience, Morphic Medical is poised to make a significant impact in the healthcare landscape, ultimately enhancing patient care and outcomes.

For more details on Morphic Medical's journey and innovations, visit morphicmedical.com or connect with them on their social media platforms.